13.31
전일 마감가:
$13.33
열려 있는:
$13.34
하루 거래량:
4.84M
Relative Volume:
0.55
시가총액:
$3.50B
수익:
$6.16B
순이익/손실:
$246.00M
주가수익비율:
14.18
EPS:
0.9387
순현금흐름:
$708.00M
1주 성능:
-0.30%
1개월 성능:
+50.74%
6개월 성능:
+72.63%
1년 성능:
+52.81%
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
OGN
Organon Co
|
13.31 | 3.50B | 6.16B | 246.00M | 708.00M | 0.9387 |
|
LLY
Lilly Eli Co
|
989.87 | 862.31B | 72.25B | 25.28B | 10.37B | 27.78 |
|
JNJ
Johnson Johnson
|
224.26 | 533.03B | 96.36B | 21.04B | 17.80B | 8.6488 |
|
ABBV
Abbvie Inc
|
207.86 | 358.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
AZN
Astrazeneca Plc
|
184.54 | 282.04B | 60.48B | 10.40B | 8.05B | 3.3297 |
|
NVS
Novartis Ag Adr
|
148.16 | 277.11B | 54.66B | 13.58B | 16.05B | 7.0171 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon & Co is the best performing healthcare stock in April - MSN
What Sparked Organon's Recent Stock Surge - Kavout
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more - MSN
Sun Pharma shares jump after Organon acquisition deal; top gainer on Nifty 50 - MSN
Mega Sun Pharma-Organon Deal | Organon A Strategic Fit For Sun Pharma, Says Macquarie Capital (Wch7sn8ZBU) - fathomjournal.org
Organon & Co. Opens with 23.72% Gain, Surpassing S&P 500's 0.8% Rise - Markets Mojo
Sun Pharma shares jump 9% as $11.75‑billion Organon buy seals entry into biosimilars, deal expected to close in 2027 - MSN
Win-win deal! Sun Pharma jumps 8% in two days with Organon zooming 42% in five daysAll about acquisition - MSN
Organon & Co (OGN) News Flow - Moomoo
What does Sun Pharma gain from its $12-billion Organon bid? - MSN
Sun Pharma’s $11.75 Billion Organon Deal: Dilip Shanghvi’s Bold Move Taking India to the World - Open Magazine
Sun Pharma to acquire Organon in $11.75 billion all-cash deal - MSN
India's largest drugmaker Sun Pharma to buy US firm Organon in $11.75 billion deal; shares jump 7% - MSN
Organon stock surges 31% on sweetened $13 billion takeover offer from Sun Pharma - MSN
MSN Money - MSN
India’s Sun Pharma takes biosimilar leap with $11.75 billion all-cash Organon acquisition - MSN
Sun Pharma's $11.75-billion Organon deal: What it means for Indian pharma M&As - MSN
'Buy' Sun Pharma shares: Up to 34% upside? What experts say on India's biggest ever pharma deal Organon - MSN
BT explainer: Why Sun Pharma's $11.75-bn Organon deal is priced below past pharma acquisitions - MSN
Sun Pharma to acquire Organon in $11.75 billion deal; eyes global top 25 spot - MSN
Organon jumps 15% as Sun Pharma agrees $11.8bn buyout - MSN
OGN (OGN) Form 144: multiple RSU vestings and dividend-equivalent share listings - Stock Titan
Sun Pharma to buy Organon in $11.75B deal, expanding global reach - MSN
Organon & Co To Go Ex-Dividend On May 11th, 2026 With 0.02 USD Dividend Per Share - Moomoo
Organon & Co. (OGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
India’s Sun Pharma plots $12 billion Organon buyout for global reach - MSN
Sun Pharmaceutical share: Brokerages turn bullish post Organon deal, peg up to 16% upside; check latest target prices - MSN
Organon SVP, corporate controller Holzbaur sells $353,080 stock By Investing.com - Investing.com Australia
Organon SVP, corporate controller Holzbaur sells $353,080 stock - Investing.com
Organon (OGN) controller sells 26,448 shares, ends direct stake - Stock Titan
OGN SEC FilingsORGANON & CO 10-K, 10-Q, 8-K Forms - Stock Titan
Organon Insider Bought Shares Worth $353,080, According to a Recent SEC Filing - marketscreener.com
OGN | Organon & Co. FinancialsIncome Statement - Quiver Quantitative
Organon SVP Lynette Holzbaur acquires $353,080 in company stock By Investing.com - Investing.com South Africa
Organon SVP Lynette Holzbaur acquires $353,080 in company stock - Investing.com
Organon (OGN) controller boosts stake with 26,448-share purchase - Stock Titan
Organon & Co stock hits 52-week high at 13.4 USD - Investing.com Australia
Organon Buyout By Sun Pharma Shifts Focus To Cash Value And Timing - Yahoo Finance
Research Alert: CFRA Retains Hold Rating On Shares Of Organon & Co. Following Q1 Results - Moomoo
Organon & Co stock hits 52-week high at 13.4 USD By Investing.com - Investing.com South Africa
How big is Organon’s biosimilar push for Sun Pharma? - MSN
Sun Pharma Signs Definitive Agreement to Acquire Organon & Company in $11.75 Billion Deal - scanx.trade
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Son rise at Sun: Decoding the architecture of Dilip Shanghvi’s global empire - Mint
Sun Pharma explores funding mix for $12 billion Organon deal - ET Pharma
Organon shares rally 16% in premarket as Sun Pharma announces buyout - MSN
Sun Pharma to acquire Organon for $11.75bn - MSN
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):